Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | AGXT | P21549 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL778647 | 0.83 | IDO1 (0.55) | TAAR1IDO1AGXTMAOB | |
| SCHEMBL5317470 | 0.83 | IDO1 (0.47) | IDO1AGXTMAOB | |
| SCHEMBL5033774 | 0.82 | KDM4E (0.41) | IDO1CA1CA2CA9DAO | |
| SCHEMBL15567567 | 0.81 | IDO1 (0.39) | TAAR1IDO1AGXTNR3C1MAOB | |
| SCHEMBL4851635 | 0.81 | TAAR1 (0.50) | TAAR1ALOX5IDO1CA1CA2 | |
| SCHEMBL15042385 | 0.81 | CA2 (0.43) | ALOX5CA1CA2CA9 | |
| SCHEMBL16666444 | 0.80 | CA1 (0.42) | TAAR1ALOX5CA1CA2CA9 | |
| SCHEMBL2284428 | 0.80 | TAAR1 (0.49) | TAAR1IDO1AGXTCA1CA2 | |
| SCHEMBL1246000 | 0.80 | CYP4F2 (0.47) | ALOX5CA1CA2CA9 | |
| SCHEMBL2878336 | 0.80 | TAAR1 (0.49) | TAAR1IDO1AGXTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868717-B2 | Tricyclic sulphonamide compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868717-B2 | Tricyclic sulphonamide compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868717-B2 | Tricyclic sulphonamide compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| EP-2925737-B1 | TRICYCLIC COMPOUNDS FOR USE IN THE TREATMENT AND/OR CONTROL OF OBESITY | ZAFGEN INC (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-2925737-B1 | TRICYCLIC COMPOUNDS FOR USE IN THE TREATMENT AND/OR CONTROL OF OBESITY | ZAFGEN INC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20160083362-A1 | TRICYCLIC SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083362-A1 | TRICYCLIC SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083362-A1 | TRICYCLIC SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2016-03-24 | — | — | US | disclosed |
| EP-2925737-A1 | TRICYCLIC COMPOUNDS FOR USE IN THE TREATMENT AND/OR CONTROL OF OBESITY | Zafgen, Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014071369-A1 | TRICYCLIC COMPOUNDS FOR USE IN THE TREATMENT AND/OR CONTROL OF OBESITY | ZAFGEN, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| EP-0485544-B1 | OXIDATIVE HAIR DYE CONTAINING 3-AMINOPHENOL DERIVATIVES, PROCESS FOR OXIDATIVE DYEING OF HAIR AND NEW 3-AMINOPHENOL DERIVATIVES | WELLA AG (DE) | 1996-10-16 | — | — | EP | disclosed |
| EP-0714894-A1 | 3-(1,2,3,6-tetrahydro-(1-alkylenearyl)-4-pyridinyl)- and 3-(1-alkylenearyl)-4-piperidinyl-1h-indoles: new 5-HT1f agonists | ELI LILLY AND COMPANY (US) | 1996-06-05 | — | — | EP | disclosed |
| US-5521197-A | ANALGESICS USING SEROTONIN ANTAGONIST | ELI LILLY AND COMPANY (US) | 1996-05-28 | — | — | US | disclosed |
| US-5468743-A | Imidazo[2,1-b]benzazepine derivatives, compositions and method of use | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-11-21 | — | — | US | disclosed |
| US-5409503-A | High color intensity red shades | WELLA AKTIENGESELLSCHAFT (DE) | 1995-04-25 | — | — | US | disclosed |
| EP-0588858-A1 | IMIDAZO 2,1-b] 3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-03-30 | — | — | EP | disclosed |
| WO-1992022551-A1 | IMIDAZO[2,1-b][3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-23 | — | — | WO | disclosed |
| EP-0518435-A1 | Imidazo[2,1-b][3]benzazepine derivatives, compositions and method of use | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-16 | — | — | EP | disclosed |
| EP-0485544-A1 | OXIDATIVE HAIR DYE CONTAINING 3-AMINOPHENOL DERIVATIVES, PROCESS FOR OXIDATIVE DYEING OF HAIR AND NEW 3-AMINOPHENOL DERIVATIVES. | WELLA AG (DE) | 1992-05-20 | — | — | EP | disclosed |
| WO-1991018583-A1 | OXIDATIVE HAIR DYE CONTAINING 3-AMINOPHENOL DERIVATIVES, PROCESS FOR OXIDATIVE DYEING OF HAIR AND NEW 3-AMINOPHENOL DERIVATIVES | WELLA AKTIENGESELLSCHAFT (DE) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083362-A1 | TRICYCLIC SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, ANPEP, METAP2 | TAAR1 1737/4885ALOX5 1223/4885IDO1 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.